查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1609144

自然殺手細胞療法市場：按治療方法、方法、應用和最終用戶 - 2025-2030 年全球預測

Natural Killer Cell Therapeutics Market by Therapeutics (NK Cell Directed Antibodies, NK Cell Therapies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

自然殺手細胞療法市場2023年估值為53.1億美元，預計到2024年將達到60.2億美元，複合年成長率為11.94%，到2030年將達到117.1億美元。

自然殺手 (NK) 細胞療法是免疫療法的一個動態前沿，重點是利用先天免疫系統靶向並消滅癌細胞和其他病原體的能力。這些治療方法涵蓋多種治療方法，包括在癌症治療、感染疾病治療和自體免疫疾病管理中的應用。對 NK 細胞療法的需求源於 NK 細胞在無需事先致敏的情況下在身體中巡邏並對抗威脅的天然能力，這為增強現有免疫療法提供了一種有前途的方法。它的應用也擴展到個人化醫療，開發針對患者的治療方法可以達到更有效的治療結果。最終用途主要涵蓋醫療機構、研究實驗室和生物製藥公司，每家公司都尋求利用和提高 NK 細胞的臨床應用能力。

主要市場統計
基準年[2023] 53.1億美元
預計年份 [2024] 60.2億美元
預測年份 [2030] 117.1億美元
複合年成長率（%） 11.94%

該市場的成長是由基因工程的進步、癌症和感染疾病的增加以及生物技術研發投資的激增所推動的。最新的商機來自人工智慧和機器學習的合作以最佳化 NK 細胞功能，以及學術界和工業界之間的合作以實現快速創新。建議強調投資重組基因技術並探索聯合治療以提高療效。然而，該市場面臨開發成本高、監管環境嚴格以及對 NK 細胞機制了解有限等挑戰，導致進展緩慢。此外，患者反應的可變性使治療開發更加複雜。創新研究可以集中在透過 CRISPR 基因編輯增強 NK 細胞的細胞毒性、開發現成的同種異體 NK 細胞療法以及應用資料分析來預測患者特異性反應。該市場競爭激烈但分散，研發活動強勁，許多新興企業瞄準利基應用。尋求引領市場的公司必須培養策略夥伴關係，優先考慮以患者為中心的方法，並靈活應對監管變化。 NK 細胞療法正在改變治療範式，並突顯現代醫學成長和創新的關鍵領域。

市場動態：快速發展的自然殺手細胞療法市場的關鍵市場洞察

自然殺手細胞治療市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球癌症盛行率上升
    • 副作用較少的標靶治療趨勢
    • 免疫療法的顯著改進
  • 市場限制因素
    • 自然殺手細胞治療藥物的高成本
  • 市場機會
    • 持續研發改良自然殺手細胞治療藥物
    • 開發新型自然殺手細胞治療藥物的優勢投資
  • 市場挑戰
    • 自然殺手細胞療法的複雜性

波特五力：駕馭自然殺手細胞治療市場的策略工具

波特的五力框架是了解自然殺手細胞治療藥物市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解自然殺手細胞治療市場的外部影響

外部宏觀環境因素在塑造自然殺手細胞治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解自然殺手細胞治療市場的競爭狀況

對自然殺手細胞治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣自然殺手細胞療法市場供應商的績效評估

FPNV定位矩陣是評估自然殺手細胞治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃自然殺手細胞治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對自然殺手細胞治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的癌症發生率正在上升
      • 副作用最小的標靶治療趨勢
      • 免疫療法的重大進展
    • 抑制因素
      • 自然殺手細胞治療藥物的高成本
    • 機會
      • 持續研究和開發以改進自然殺手細胞療法
      • 新開發自然殺手細胞治療藥物的有利投資
    • 任務
      • 與自然殺手細胞治療藥物相關的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自然殺手細胞治療市場

  • 針對 NK 細胞的抗體
  • NK細胞療法

第7章自然殺手細胞治療藥物市場分析

  • 抗體依賴性細胞介導的細胞毒性（ADCC）
  • 雙特異性抗體

第8章自然殺手細胞治療藥物市場：依應用分類

  • 急性感染疾病
  • 癌症
  • 消化系統疾病
  • 免疫增生性疾病

第9章自然殺手細胞治療藥物市場：依最終使用者分類

  • 醫院
  • 研究/學術機構
  • 專科診所

第10章美洲自然殺手細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區自然殺手細胞治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲自然殺手細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Acepodia Inc.
  • Affimed NV
  • BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
  • Celgene Corporation by Bristol-Myers Squibb Company
  • Celularity Inc.
  • Century Therapeutics, Inc.
  • Cytovac A/S
  • Dragonfly Therapeutics, Inc.
  • EMERcell
  • Fate Therapeutics, Inc.
  • Fortress Biotech, Inc.
  • Gamida Cell Ltd.
  • Glycostem Therapeutics BV
  • iCell Gene Therapeutics LLC
  • ImmunityBio, Inc. by NantWorks LLC
  • Innate Pharma SA
  • Kiadis Pharma NV by Sanofi SA
  • Merck KGaA
  • MiNK Therapeutics, Inc.
  • Multimmune GmbH
  • Nkarta, Inc.
  • PersonGen BioTherapeutics
  • Phio Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-5C6F41F5AFEC

The Natural Killer Cell Therapeutics Market was valued at USD 5.31 billion in 2023, expected to reach USD 6.02 billion in 2024, and is projected to grow at a CAGR of 11.94%, to USD 11.71 billion by 2030.

Natural Killer (NK) Cell Therapeutics represent a dynamic frontier within immunotherapy, focusing on leveraging the innate immune system's ability to target and destroy cancer cells and other pathogens. The scope of these therapeutics encompasses a variety of treatment modalities, including cancer therapies, infectious disease treatments, and applications in auto-immune disorder management. The necessity for NK cell therapeutics arises from their natural ability to patrol the body and combat threats without prior sensitization, offering a promising approach to enhance existing immune therapies. The application extends into personalized medicine, where patient-specific treatment regimens can be developed for more effective outcomes. End-use primarily spans healthcare facilities, research laboratories, and biopharmaceutical companies, each seeking to harness and refine NK cell capabilities for clinical use.

KEY MARKET STATISTICS
Base Year [2023] USD 5.31 billion
Estimated Year [2024] USD 6.02 billion
Forecast Year [2030] USD 11.71 billion
CAGR (%) 11.94%

Growth in this market is driven by advancements in genetic engineering, increasing incidences of cancer and infectious diseases, and burgeoning investment in biotech R&D. Latest opportunities stem from collaborations with artificial intelligence and machine learning to optimize NK cell function, as well as partnerships between academia and industry for rapid innovation. Recommendations emphasize investing in genetic modification technologies and exploring combination therapies to enhance efficacy. However, the market faces challenges such as high development costs, stringent regulatory landscapes, and limited understanding of NK cell mechanisms, which can slow progress. Moreover, the variability in patient response further complicates therapeutic development. Innovative research could focus on enhancing NK cell cytotoxicity through CRISPR gene editing, developing off-the-shelf allogeneic NK cell therapies, and applying data analytics to predict patient-specific responses. The market is competitive yet fragmented, marked by intense R&D activities and numerous start-ups targeting niche applications. Companies looking to lead should foster strategic partnerships, prioritize patient-centric approaches, and remain agile to regulatory changes. As the therapeutic landscape evolves, NK cell therapeutics stand to revolutionize treatment paradigms, highlighting a pivotal area of growth and innovation in modern medicine.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Natural Killer Cell Therapeutics Market

The Natural Killer Cell Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer worldwide
    • Inclination towards targeted therapies with minimal side effects
    • Significant improvements in immunotherapy
  • Market Restraints
    • High cost associated with natural killer cell therapeutics
  • Market Opportunities
    • Ongoing R&D to improve natural killer cell therapeutics
    • Favorable investments for development of novel natural killer cell therapeutics
  • Market Challenges
    • Complexity associated with natural killer cell therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Natural Killer Cell Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Natural Killer Cell Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Natural Killer Cell Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Natural Killer Cell Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Natural Killer Cell Therapeutics Market

A detailed market share analysis in the Natural Killer Cell Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Natural Killer Cell Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Natural Killer Cell Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Natural Killer Cell Therapeutics Market

A strategic analysis of the Natural Killer Cell Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Natural Killer Cell Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acepodia Inc., Affimed N.V., BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc., Celgene Corporation by Bristol-Myers Squibb Company, Celularity Inc., Century Therapeutics, Inc., Cytovac A/S, Dragonfly Therapeutics, Inc., EMERcell, Fate Therapeutics, Inc., Fortress Biotech, Inc., Gamida Cell Ltd., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio, Inc. by NantWorks LLC, Innate Pharma S.A., Kiadis Pharma N.V. by Sanofi S.A., Merck KGaA, MiNK Therapeutics, Inc., Multimmune GmbH, Nkarta, Inc., PersonGen BioTherapeutics, Phio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Natural Killer Cell Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics, market is studied across NK Cell Directed Antibodies and NK Cell Therapies.
  • Based on Approaches, market is studied across Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies.
  • Based on Application, market is studied across Acute Infectious Diseases, Cancer, Gastrointestinal Diseases, and Immunoproliferative Disorders.
  • Based on End User, market is studied across Hospitals, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer worldwide
      • 5.1.1.2. Inclination towards targeted therapies with minimal side effects
      • 5.1.1.3. Significant improvements in immunotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with natural killer cell therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to improve natural killer cell therapeutics
      • 5.1.3.2. Favorable investments for development of novel natural killer cell therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity associated with natural killer cell therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Natural Killer Cell Therapeutics Market, by Therapeutics

  • 6.1. Introduction
  • 6.2. NK Cell Directed Antibodies
  • 6.3. NK Cell Therapies

7. Natural Killer Cell Therapeutics Market, by Approaches

  • 7.1. Introduction
  • 7.2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  • 7.3. Bispecific Antibodies

8. Natural Killer Cell Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Infectious Diseases
  • 8.3. Cancer
  • 8.4. Gastrointestinal Diseases
  • 8.5. Immunoproliferative Disorders

9. Natural Killer Cell Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research & Academic Institutes
  • 9.4. Specialty Clinics

10. Americas Natural Killer Cell Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Natural Killer Cell Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Natural Killer Cell Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acepodia Inc.
  • 2. Affimed N.V.
  • 3. BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
  • 4. Celgene Corporation by Bristol-Myers Squibb Company
  • 5. Celularity Inc.
  • 6. Century Therapeutics, Inc.
  • 7. Cytovac A/S
  • 8. Dragonfly Therapeutics, Inc.
  • 9. EMERcell
  • 10. Fate Therapeutics, Inc.
  • 11. Fortress Biotech, Inc.
  • 12. Gamida Cell Ltd.
  • 13. Glycostem Therapeutics B.V.
  • 14. iCell Gene Therapeutics LLC
  • 15. ImmunityBio, Inc. by NantWorks LLC
  • 16. Innate Pharma S.A.
  • 17. Kiadis Pharma N.V. by Sanofi S.A.
  • 18. Merck KGaA
  • 19. MiNK Therapeutics, Inc.
  • 20. Multimmune GmbH
  • 21. Nkarta, Inc.
  • 22. PersonGen BioTherapeutics
  • 23. Phio Pharmaceuticals Inc.
  • 24. Regeneron Pharmaceuticals Inc.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. NATURAL KILLER CELL THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NATURAL KILLER CELL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NATURAL KILLER CELL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NATURAL KILLER CELL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NATURAL KILLER CELL THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL DIRECTED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ACUTE INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY IMMUNOPROLIFERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. NATURAL KILLER CELL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. NATURAL KILLER CELL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023